MetaCap

Bioventus (BVS) vs Carlsmed (CARL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Carlsmed (CARL) has outperformed Bioventus (BVS) over the past year, gaining 39.5% versus a gain of 36.5%. Bioventus is the larger company by market cap ($676.5 million vs $477.4 million), about 1.4 times the size, while Carlsmed is growing revenue faster (+85.9% vs -0.9%). Bioventus converts more of its revenue into profit, with a net margin of 4.0% versus -58.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BVS+36.46%CARL+39.47%
+118%+41%-36%
Nov 21, 20251 yearNov 20, 2026
BVS+50.38%CARL+20.14%
+136%+45%-47%
Jul 21, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BVS versus CARL key metrics
MetricBVSCARL
Share price$9.88$17.42
Market cap$676.53M$477.38M
1-day change-0.70%+1.16%
YTD return+32.80%+41.05%
1-year return+36.46%+39.47%
5-year return-21.02%—
P/E ratio (TTM)12.20—
Forward P/E11.13—
EPS (TTM)$0.81$-1.13
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$568.09M$50.51M
Revenue growth (YoY)-0.91%+85.94%
Net income (latest FY)$22.73M$-29.63M
Gross margin68.33%75.31%
Operating margin9.50%-60.53%
Net margin4.00%-58.67%
52-week high$15.89$19.15
52-week low$7.02$8.50
Distance from 52-week high-37.83%-9.05%
Analyst consensusnonestrong_buy
Avg. price target upside+68.02%+26.29%
Average volume536.81K112.80K
Shares outstanding68.47M27.40M
Employees960127
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Bioventus is more profitable, keeping 4.0 cents of every revenue dollar as net income versus -58.7 cents for Carlsmed.
  • Carlsmed grew revenue faster in its latest fiscal year (+85.94% vs -0.91%).

About Bioventus

BVS stock →

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.

Health Care · Medical/Dental Instruments · 960 employees

About Carlsmed

CARL stock →

Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures.

Health Care · Medical/Dental Instruments · 127 employees

BVS vs CARL FAQ

Which is bigger, Bioventus or Carlsmed?

Bioventus (BVS) is larger, with a market capitalization of $676.53M compared with $477.38M for Carlsmed (CARL).

Which stock has performed better over the past year, BVS or CARL?

CARL returned +39.47% over the past 12 months, compared with +36.46% for BVS (price return, excluding dividends). Past performance does not predict future results.

Are Bioventus and Carlsmed in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons